摘要
T细胞受体 (TCR )对特异性肽 MHC复合物的识别是产生适应性免疫应答的关键步骤。因此 ,TCR介导的对T细胞活化抑制的拮抗作用可望成为一种特异性强而几乎没有副作用的免疫干预机制。
出处
《现代免疫学》
CAS
CSCD
北大核心
2004年第1期80-82,共3页
Current Immunology
参考文献20
-
1[1]Anderton SM. Peptide-based immunotherapy of autoimmunity:a path of puzzles paradoxes and possibilities[J]. Immunology,2001,104:367.
-
2[2]Thomson CT,Kalergis AM,Sacchettini JC,et al. A structural difference limited to one residue of the antigenic peptide can profoundly altered biological outcome of the TCR-peptide MHC class I interaction[J]. J Immunol,2001,166:3994.
-
3[3]de Magistris MT,Alexander J,Coggeshall M,et al. Analog antigen/MHC complexes act as antagonists of T cell receptor[J]. Cell,1992,68:625.
-
4[4]Cochran JR,Cameron TO,Storn LJ. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligoers[J]. Immunity,2000,12:241.
-
5[5]Valitutti S,Müller S,Cella M,et al. Serial triggering of many T-cell receptors by a few peptide-MHC complexes[J]. Nature,1995,375:148.
-
6[6]Bechamann MF,Speiser DE,Zakarian A,et al. Inhibition of TCR trig-gering by a spectrum of altered peptide ligands suggests the mechanism for TCR antagonism[J]. Eur J Immunol,1998,28:3110.
-
7[7]Yang W,Grey HM. Study of the mechanism of TCR antagonism using dual-TCR-expressing T cells[J]. J Immunol,2003,170:4532.
-
8[8]Chmielowski B,Pacholczyk B,Kraj P,et al. Presentation of antagonist peptides to naive CD4+T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells[J]. Proc Natl Acad Sci USA,2002,99:15012.
-
9[9]Salzmann M,Bachmann MF. The role of T-cell receptor dimerization for T cell antagonism and cell specificity[J]. Mol Immunol,1998,35:271.
-
10[10]Dittel BN,Stefanova I,Germain RN,et al. Cross-antagonism of a T cell clone expressing two distinct T cell recepors[J]. Immunity,1999,11:289.
同被引文献20
-
1董薇,蔡美英.树突状细胞与T细胞免疫反应结果研究进展[J].中国免疫学杂志,2005,21(2):155-158. 被引量：8
-
2赵宁,贾红伟,吴萍,鞠大宏,徐世杰,肖诚,吕爱平.从黏膜免疫探讨中医治疗类风湿性关节炎的作用机理[J].中国中医基础医学杂志,2002,8(3):6-8. 被引量：7
-
3王艳艳,白云,宋建勋,杨晓亚.OX40信号上调Survivin表达对CD4^+T淋巴细胞增殖存活的影响[J].免疫学杂志,2005,21(2):81-83. 被引量：3
-
4吴东海.经口诱导的免疫耐受与类风湿关节炎[J].中华内科杂志,1997,36(4):279-281. 被引量：2
-
5[19]陈先赋.四川名医传(上集)·补晓岚[M].成都:四川科学技术出版社,1991
-
6吴生元 吴元坤.吴佩衡医案[M].昆明:云南人民出版社,1979..
-
7曾升平,陈晓玲,杨莉,陈静,李媛.温阳益气法对虚寒型自身免疫病患者免疫调节作用的初步观察[J].中国中医基础医学杂志,1999,5(3):48-49. 被引量：2
-
8汪厚平,马宝骊.类风湿关节炎免疫治疗的研究进展[J].上海免疫学杂志,1999,19(5):313-315. 被引量：7
-
9朱平,王彦宏,冷南,王树宽,吴振彪,解慧,张惠琴,樊春梅.口服Ⅱ型胶原诱导免疫耐受对佐剂性关节炎免疫病理和Th亚群的作用[J].中华风湿病学杂志,2000,4(5):289-292. 被引量：10
-
10张进安.自身免疫性疾病的T细胞受体研究及应用进展[J].国外医学（生理病理科学与临床分册）,2001,21(3):178-180. 被引量：2
二级引证文献4
-
1赵辉,余超,廖志敏.曾升平教授运用补中益气汤加减治疗系统性红斑狼疮脱发的经验[J].云南中医中药杂志,2009,30(3):2-3. 被引量：3
-
2余超,赵辉,廖志敏.曾升平治疗寒湿型类风湿关节炎经验[J].山西中医,2009,25(4):7-8. 被引量：9
-
3郑秀春.类风湿关节炎的免疫治疗进展[J].中国医药指南,2012,10(33):76-77.
-
4李先富,宗良玉,高景峰,方琳,曹梦琴.细胞治疗技术用于治疗类风湿性关节炎(附6例报告)[J].中国医学工程,2013,21(2):177-177.
